FDA Approves Xeomin® (incobotulinumtoxinA) for Cervical Dystonia and Blepharospasm

Here are some snippets from a press release:

FDA Approves Merz Pharmaceuticals' Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm

GREENSBORO, N.C., Aug. 2 /PRNewswire/ -- Merz Pharmaceuticals today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin® (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

More than 84,000 patients have been treated with XEOMIN worldwide since 2005. The U.S. is the 20th country to approve XEOMIN for the treatment of cervical dystonia and blepharospasm.